Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Adaptimmune Therapeutics PLC changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 82 | 1 | 92 | +11 |
| Shares | 111.7M | 1.77K | 111.7M | −5.70K (0.0%) |
| Value | $475.7M | $8.00K | $577.3M | +$101.6M (+21.4%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 1,553,800 | $8.03M | 0.04% |
| Eversept Partners, LP | 444,887 | $2.30M | 0.18% |
| Balyasny Asset Management LLC | 259,413 | $1.34M | 0.01% |
| Erste Asset Management GmbH | 90,000 | $468.0K | 0.01% |
| ACT Capital Management, LLC | 90,000 | $465.0K | 0.24% |
| ExodusPoint Capital Management, LP | 86,202 | $446.0K | 0.01% |
| Marshall Wace North America L.P. | 58,847 | $304.0K | 0.00% |
| Virtu Financial LLC | 47,542 | $246.0K | 0.02% |
| Blair William & Co | 40,000 | $207.0K | 0.00% |
| Trexquant Investment LP | 23,609 | $122.0K | 0.01% |
| Tudor Investment Corp Et Al | 16,004 | $83.0K | 0.00% |
| FNY Investment Advisers, LLC | 12,500 | $64.0K | 0.03% |
| Blueshift Asset Management, LLC | 11,933 | $62.0K | 0.00% |
| Wealthspire Advisors, LLC | 11,750 | $61.0K | 0.00% |
| Toroso Investments, LLC | 10,554 | $55.0K | 0.00% |
| Eagle Bay Advisors LLC | 3,880 | $20.0K | 0.01% |
| Quadrant Capital Group LLC | 3,220 | $17.0K | 0.00% |
| Total Clarity Wealth Management, Inc. | 1,200 | $6.00K | 0.00% |
Sold out (7)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Avoro Capital Advisors LLC | 2,024,400 | $8.62M |
| Capital International Investors | 1,321,200 | $5.63M |
| Renaissance Technologies LLC | 303,495 | $1.29M |
| Jump Financial, LLC | 128,200 | $546.0K |
| HRT Financial LP | 42,621 | $181.0K |
| Credit Agricole S A | 30,000 | $128.0K |
| Sigma Planning Corp | 10,209 | $43.0K |
Not filed for Q3 2021 yet (1)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Hoover Financial Advisors, Inc. | 1,766 | $8.00K |